Head-To-Head Comparison: Nautilus Biotechnology (NAUT) and Its Peers – Defense World

Nautilus Biotechnology (NASDAQ:NAUT Get Rating) is one of 42 public companies in the Analytical instruments industry, but how does it compare to its rivals? We will compare Nautilus Biotechnology to similar companies based on the strength of its dividends, analyst recommendations, risk, earnings, institutional ownership, valuation and profitability.

Insider and Institutional Ownership

47.9% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 60.0% of shares of all Analytical instruments companies are owned by institutional investors. 13.4% of shares of all Analytical instruments companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

This table compares Nautilus Biotechnology and its rivals net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Nautilus Biotechnology and its rivals, as provided by MarketBeat.

Nautilus Biotechnology currently has a consensus price target of $8.67, suggesting a potential upside of 131.73%. As a group, Analytical instruments companies have a potential upside of 35.16%. Given Nautilus Biotechnologys stronger consensus rating and higher probable upside, research analysts plainly believe Nautilus Biotechnology is more favorable than its rivals.

Valuation & Earnings

This table compares Nautilus Biotechnology and its rivals gross revenue, earnings per share (EPS) and valuation.

Nautilus Biotechnologys rivals have higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Nautilus Biotechnology rivals beat Nautilus Biotechnology on 8 of the 12 factors compared.

About Nautilus Biotechnology (Get Rating)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
Head-To-Head Comparison: Nautilus Biotechnology (NAUT) and Its Peers - Defense World